Carcinogen Hazard Assessment Monographs Program (R01 Clinical Trial Not Allowed)
This grant funds research to systematically review and evaluate evidence on substances that may cause cancer, producing monographs to inform health policy and cancer prevention.
Funder: National Institutes of Health
Due Dates: February 9, 2027 (Application deadline)
Funding Amounts: $700,000 award floor and ceiling; $800,000 estimated total program funding; 1 expected award
Summary: Supports critical, systematic evaluation of scientific evidence on carcinogenic hazards to humans to advance cancer research, control, and prevention.
Key Information: Clinical trials and foreign components are not allowed; foreign organizations may apply.
Description
The National Cancer Institute (NCI), part of the National Institutes of Health, invites applications to the Carcinogen Hazard Assessment Monographs Program (CHAMP) Initiative through an R01 funding opportunity. The program seeks meritorious proposals to critically and systematically evaluate scientific evidence on carcinogenic hazards to humans.
CHAMP focuses on identifying potential carcinogens, an activity essential to guiding and advancing cancer research and informing cancer control and prevention efforts. Its scope centers on evaluation of the scientific evidence concerning human carcinogenic hazards. The opportunity is designated “Clinical Trial Not Allowed” and is offered under funding opportunity number RFA-CA-28-013.
